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Abstract In this study, we explored the local cytokine/chemokine profiles in patients with
active pulmonary or pleural tuberculosis (TB) using multiplex protein analysis of bronchoalveolar
lavage and pleural fluid samples. Despite increased pro-inflammation compared to the
uninfected controls; there was no up-regulation of IFN-γ or the T cell chemoattractant CCL5. tuberculosis, Mycobacterium tuberculosis; HIV, Human Immunodeficiency Virus; Th, T helper; CTL,
cell; Treg, regulatory T cell; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; Ig,
cytokine signaling; JAK, Janus Kinases; STAT, Signal Transducers and Activators of Transcription; BAL,
ral blood mononuclear cell; TST, tuberculin skin test; LJ, Løwenstein–Jensen; BCG, Bacillus Calmette
tical density; Ct, cycle threshold; M-CSF, macrophage colony-stimulating factor; GMCSF, granulocyte
; IL-1RA, IL-1 receptor antagonist; IL-2R, IL-2 receptor; MOI, multiplicity of infection; PTB, pulmonary
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in the lung of patients with pulmonary TB. Instead, elevated levels of IL-4 and CCL4 were
associated with high mycobacteria-specific IgG titres as well as SOCS3 (suppressors of cytokine
signaling) mRNA and progression of moderate-to-severe disease. Contrary, IL-4, CCL4 and SOCS3
remained low in patients with extrapulmonary pleural TB, while IFN-γ, CCL5 and SOCS1 were
up-regulated. Both SOCS molecules were induced in human macrophages infected with
Mycobacterium tuberculosis in vitro. The Th2 immune response signature found in patients
with progressive pulmonary TB could result from inappropriate cytokine/chemokine responses
and excessive SOCS3 expression thatmay represent potential targets for clinical TBmanagement.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. IntroductionTuberculosis (TB) is one of the most wide-spread human
bacterial infections. The lethal synergy between TB and HIV
infections is also a major challenge to public health and hence
there is a need to understand the cellular and molecular
mechanisms responsible for the progression of TB in both
HIV-negative and HIV-positive individuals [1]. Successful
control of Mycobacterium tuberculosis (M. tuberculosis) as
well as HIV infection is dependent on cell mediated immunity
that is orchestrated by multiple cytokines and chemokines
involved in the activation and recruitment of cells to the site
of infection [2,3]. Pro-inflammatory cytokines (IL-12, TNF-α)
as well as Th1 (IL-2, IFN-γ) and Th17 (IL-17, IL-22) effector
cytokines specifically promote classical activation of macro-
phages (M1) and activation of CD8+ cytolytic T cells (CTLs) or
NK/NKT cells that trigger target cell and bacterial killing [3].
Here, HIV infection may impair cellular immunity at the site of
M. tuberculosis infection by interfering with the recruitment
and function of macrophages and CD4+ T cells [4].
We have previously reported an impairment of Th1/Th17
and CD8+ CTL responses in human granulomatous TB lesions in
both the lymph nodes [5] and lung [6] that may be the
consequence of an induction of Th2 and regulatory T cell
(Treg) responses [5] Consistent with these findings, growing
evidence suggests that a Th1/Th2 balance is crucial to control
the progression of active TB disease [7,8]. IL-12, IFN-γ and
TNF-α contribute to the induction of Th1-mediated protection
in TB, while increased IL-4 levels promote the development
of a Th2 response that efficiently antagonizes protective
cytokines and results in loss of TB control [9]. Th2 cytokines
have been shown to induce alternative macrophage activation
(M2) that involves a less bactericidal state of the macrophage
[10]. Th2 cytokines can also inhibit autophagy, which is a
physiological process known to enhance intracellular degra-
dation of mycobacteria [11]. On the contrary, Th2 responses
promote antibody-mediated immunity that may fail to confer
resistance in intracellular M. tuberculosis infection [12]. The
Th1/Th2 balance is likely affected by different chemokines
[13] produced by various cell types. Inflammatory chemokines
such as CCL5, CXCL9 and CXCL10, selectively attract and
recruit Th1 cells from blood to sites of infection while other
chemokines such as CCL3 and CCL4 may promote Th2
immunity [13,14]. AlthoughM. tuberculosis is a potent inducer
of several inflammatory chemokines [15], little is known about
the local chemokine profile in the chronic phase of human TBinfection. The Th1/Th2 balance could also be controlled by a
family of regulatory proteins called suppressors of cytokine
signaling (SOCS) [16]. SOCS are molecules induced by
cytokines or other stimuli and function as negative feedback
inhibitors by binding either to cytokine receptors or to
associated Janus Kinases (JAK), to inhibit the activation of
Signal Transducers and Activators of Transcription (STAT) [16].
SOCS1 and SOCS3 are the most studied members that inhibit
STAT1 and STAT3 signaling, respectively [16]. Accumulating
data support a central role of SOCS proteins in the regulation
of immune polarization, which may be highly relevant for the
outcome of different infectious diseases [16].
In this study, we aimed to discover adverse immune
response signatures relevant to the progression and severity
of active TB disease in HIV-negative and HIV-positive patients.
We analyzed immune mediators locally in the lung or pleura in
comparison with peripheral blood, in patients with pulmonary
TB or pleural TB. While the lung is the most common site ofM.
tuberculosis infection, extrapulmonary TB including pleural
TB without concomitant pulmonary infection, often repre-
sents a milder clinical form of disease [17]. Low levels of
IFN-γ, IL-17 and CCL5 along with enhanced levels of IL-4, CCL4
and regulatory SOCS1 and SOCS3 proteins were observed in the
lungs of patients with active pulmonary TB compared to the
controls. The Th2-like immune signature in combination with
enhanced SOCS3 expression was more prominent in severe
forms of TB disease and was also associated with elevated
antibody responses in patients with pulmonary TB. Future
diagnostic and therapeutic approaches of clinical TB may
therefore consider quantifying and targeting Th2 and SOCS3
regulated immune response pathways.
2. Material and methods
2.1. Study subjects and clinical diagnosis
The study subjects were recruited at the Chest Unit,
Department of Internal Medicine, Black Lion University Hospi-
tal, Addis Ababa, Ethiopia, after providing signed informed
consent. The study was approved by the National Ethical
Committees in both Ethiopia and Sweden. Patients and controls
were enrolled according to the flow chart illustrated in Fig. 1.
Inclusion criteria: HIV-negative and HIV-positive sputum
smear-negative individuals N18 years old with clinical symp-
toms of suspected TB. Exclusion criteria: patients with miliary
TB, a history of previous TB, or N1 week of antimicrobial
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not consent to HIV screening. The initial clinical diagnosis of TB
was based on: 1) Typical clinical symptoms of more than
4 weeks duration including persistent cough, general illness,
fever, sweating, and weight loss; and 2) chest X-ray revealing
either pulmonary infiltrates/lesions or pleural effusions. A
diagnosis of pulmonary TB was later confirmed by a positive
M. tuberculosis culture of bronchoalveolar lavage (BAL) fluid
samples, while extrapulmonary pleural TB was confirmed by
cyto-histopathology of pleural fluid and biopsy samples. Thus,
BAL and pleura fluid samples were obtained as part of the
routine diagnosis. Patients with active TB (n = 58) received
standard anti-TB chemotherapy for 6 months including rifam-
picin, isoniazid, pyrazinamide and ethambutol. The response to
treatment was monitored at 2, 5, and 8 months and clinical
improvement and radiologic resolution of pulmonary lesions
were used as retrospective diagnostic criteria for culture-
negative pulmonary TB patients with clinical TB (n = 11).
HIV-negative individuals with a minor hemoptysis (n = 10)
were used as controls for the pulmonary TB cases (n = 35).
These subjects were initially screened for TB, but were finally
diagnosed as healthy individuals with a single episode of
hemoptysis caused by a minor bronchial wall irritation. The
hemoptysis did not recur and no signs of inflammatory
conditions, infection or cancer were found. HIV-negative
patients with pleural diseases other than TB (n = 5) were used
as controls for the pleural TB cases (n = 23) and included
malignancies (n = 3), congestive heart failure (n = 1) and
systemic lupus erythematosus (n = 1). All the controls had a
negative tuberculin skin test (TST).2.2. Chest X-ray grading
Chest X-ray was used to grade disease severity among
pulmonary TB patients at the time of diagnosis into mild
(grade 1), moderately severe (grade 2) or severely advancedScreening sputum-negative patie
using clinical symptoms, chestX-ray, M. tuberculo
Lung diseases (n=56)
Pulmonary TB (n=35)
TST-pos: 30/35
HIV-pos: 13/35 - Malignancies (n=4)
- Pneumonia (n=3)
- Bronchiectasis (n=3)
TST-pos: 7/10
HIV-pos: 2/10 
- Haemoptysis (n=11)
TST-pos: 0/11
HIV-pos: 1/11
Pulmonary controls (n=10)
Other diseases (n=21)
TST-pos: 0/10
HIV-pos: 0/10
Figure 1 Flow chart of participants. Sputum-negative patients w
M. tuberculosis culture or cyto-histopathology of clinical specim
malignancies, pneumonia and bronchiectasis (abnormal chest X-ray
single episode of hemoptysis were finally diagnosed as healthy indiv
malignancies, congestive heart failure (CHF) and systemic lupus er
etiology, pleural biopsies were non-diagnostic and/or cytology was
were included as pulmonary or pleural controls. Patients and control(grade 3) TB disease based on visual examination of the
chest X-rays using the diagnostic standards and classification
of TB by the American Thoracic Society, National Tubercu-
losis Association of the USA. Accordingly, mild TB disease
(n = 19 pulmonary TB patients) was defined as non-confluent
unilateral or bilateral infiltrates without noticeable cavita-
tions. The extent did not exceed the volume of the lung on
one side above the second costochondral junction or the 4th
or 5th vertebrae. Moderate-to-severe TB disease (n = 16
pulmonary TB patients) was defined as disseminated lesions
of slight to moderate density that extended throughout the
total volume of one lung or equivalent volume in both lungs
or dense and confluent lesion(s) that were limited to one
third of the volume of one lung lobe. Moderately severe TB
involved cavitations with a diameter b 4 cm (n = 13 pulmo-
nary TB patients), while severely advanced TB involved
cavitations with a diameter N 4 cm (n = 3 pulmonary TB
patients).2.3. Clinical samples and HIV screening
Blood, BAL or pleural fluid samples were collected from the
study subjects to be used for diagnostic and research
purposes. Blood samples (20 ml) obtained were used for
peripheral CD4/CD8 T cell counts (FACSCount; BD, Franklin
Lakes, NJ), to determine HIV status, HIV viral load (Abbott
real-time HIV-1 PCR; Abbott Molecular, Des Plaines, IL) and
for immunological analysis. HIV screening was performed at
the Black Lion University Hospital using a national algorithm
in three steps: 1) HIV (1 + 2) Antibody Kit (KHB Shanghai
Kehua Bio-engineering; Shanghai, China); 2) HIV 1/2 STAT-
PAK Kit (CHEMBIO Diagnostic Systems; Medford, NY); and 3)
Uni-Gold HIV test (Trinity Biotech; Co Wicklow, Ireland).
Pre-test counseling was offered to all subjects whereas
post-test counseling was provided to HIV-positive subjects
by a trained counselor. Antiretroviral therapy was offerednts for TB (n=90) 
sis culture or cyto-histopathology.
Pleural diseases (n=33)
One patient did not consent.
Pleural TB (n=23)
TST-pos: 20/23
HIV-pos: 7/23 -Malignancies(n=3)
- CHF (n=1)
- SLE (n=1) 
TST-pos: 0/5
HIV-pos: 0/5
- Unclear etiology (n=5)
TST-pos: 4/5
HIV-pos: 2/5
Other diseases (n=10)
Pleural controls (n=5)
TST-pos: 0/5
HIV-pos: 0/5
ere screened using clinical symptoms and chest X-ray as well as
en. Individuals with other lung diseases than TB included
) or a minor hemoptysis (normal chest X-ray). Subjects with a
iduals. Individuals with other pleural diseases than TB included
ythematosus (SLE). In patients with pleural diseases of unclear
not consistent with TB. Only TST- and HIV-negative individuals
s that were selected for further analysis are shown in the boxes.
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b350 cells/ml. Treatment for HIV was provided for free by
the government of Ethiopia (the Federal Ministry of Health).
PBMCs and plasma were isolated from whole blood using
cell preparation tubes (CPT; BD). Plasma samples were
aliquoted and stored at −80 °C for cytokine/chemokine
protein analysis, while PBMCs (5 × 106) were resuspended in
300 μl of RNAlater (Life Technologies, Invitrogen, Carlsbad,
CA) and stored at −80 °C for mRNA analysis. Bronchoscopy
was performed not only on pulmonary TB patients with
abnormal chest X-ray findings (n = 35) but also on individuals
with a normal chest X-ray who had a minor bleeding caused
by a minor bronchial wall irritation (n = 10). In patients with
pulmonary TB, a flexible fiberoptic bronchoscope (BF type
P20D bronchoscope, Olympus, Tokyo, Japan) was used to
collect BAL fluid from the affected bronchi based on the
radiological findings. In the pulmonary control group, BAL
fluid was collected from the right middle lobe bronchus
using flexible bronchoscopy. A total of 120 ml normal saline
were sequentially instilled and immediately retrieved. In
patients with extrapulmonary pleural TB, thoracentesis was
used to collect 50 ml fluid from the pleural cavity.
An aliquot of the BAL and pleural fluid was used for
M. tuberculosis culture or cytology, respectively. The
remaining BAL and pleura fluid were centrifuged at
1400 rpm for 25 min. Supernatants were stored at −80 °C
for cytokine/chemokine protein analysis, while BAL and
pleura cells (5 × 106) were resuspended in RNAlater and
stored at −80 °C for mRNA analysis.
2.4. M. tuberculosis culture and
cyto-histopathology
M. tuberculosis culture of BAL fluid was performed at the
Armauer Hansen Research Institute, Addis Ababa, Ethiopia,
using the established Løwenstein–Jensen (LJ) methodology.
After NaOH (4%) treatment, washing and centrifugation of BAL
fluids, cell pellets were resuspended in 1.5 ml of 7H9 media
(Sigma-Aldrich, Fluka, St. Louis, MO) from which an aliquot
(20–30 μl) was inoculated in LJ-media and incubated at 37 °C
for 8 weeks with weekly read-out of bacterial growth. Cytology
of cell samples from pleural fluid and histology of paraffin-
embedded pleural tissue biopsies involved hematoxylin and
eosin staining performed at the Department of Pathology, Black
Lion University Hospital, Addis Ababa, Ethiopia. M. tuberculo-
sis-positive specimens revealed a granulomatous reaction with
multinucleated giant cells, epithelioid cells, numerous lym-
phocytes and necrotic material consistent with TB.
2.5. Multiplex luminex assay
Cytokine and chemokine responses in fluid and plasma
samples obtained from the study subjects were assessed
using a human standard cytokine 25-plex panel (LHC0009:
IL-1β, IFN-α, TNF-α, IL-6, IL-12, IL-7, IL-2, IFN-γ, IL-17, IL-4,
IL-5, IL-13, IL-15, IL-10, IL-1RA, IL-2R, IL-8, GMCSF, Eotaxin,
CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10), a human ultra-
sensitive cytokine 10-plex antibody bead kit (LHC6004:
IL-1β, TNF-α, IL-6, IL-2, IFN-γ, IL-4, IL-5, IL-10, IL-8,
GMCSF) and a human chemokine 10-plex antibody bead kit
(LHC6001: Eotaxin, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8,CXCL1, CXCL9, CXCL10) (Invitrogen). The multiplex luminex
assay was performed according to the manufacturer's
instructions using the Bio-Plex Luminex detection system.
Data were analyzed by the Bio-Plex manager 4.0 curve
fitting software using the five-parametric algorithm. Cyto-
kine concentrations in BAL and plasma ranged from 0.2 to
1300 pg/mg of total protein while chemokine concentrations
in BAL and plasma ranged from 1 to 30,000 pg/mg of total
protein. Cytokine and chemokine concentrations in pleural
fluid samples ranged from 2 to 130 pg/ml and from 15 to
1000 pg/ml, respectively.
2.6. BCG-specific IgG ELISA
The release of mycobacteria-specific IgG antibodies in fluid
and plasma samples obtained from the study subjects was
quantified using a Bacillus Calmette Guerin (BCG)-specific
ELISA. The BCG ELISA detects IgG antibodies that are specific
for mycobacterial epitopes of the BCG vaccine that is derived
from an attenuated Mycobacterium bovis strain. Briefly, a
BCG vaccine antigen (kindly provided by Japan BCG Labora-
tories, Tokyo, Japan) was used to coat Maxisorb plates (Nunc,
Roskilde, Denmark) overnight at 4 °C. The plates werewashed
with PBS-0.05% Tween-20 (Sigma, Sweden) and blocked with
PBS-10% FCS. Plasma (diluted 1:500), BAL (diluted with
respect to total protein concentration in each sample) or
pleura (diluted 1:400) fluid samples from patients and controls
were added (100 μl/well) and incubated for 2 h at 37 °C
before washing and addition of a rabbit anti-human IgG
horseradish peroxidase conjugate (Jackson Immunoresearch
Laboratories, West grove, PA) for 2 h at room temperature.
Dilution buffer (PBS-10% FCS) was used as a negative control.
The enzyme–substrate reaction was developed after 20 min
using a O-phenylenediamine (OPD) (Sigma) substrate solution.
BCG-specific IgG titers were expressed as optical density (OD)
measured at 492 nm and multiplied by the dilution factor.
2.7. Protein determination with BCA
Total protein content in BAL (average 0.3 mg/ml; range
0.04–2.2 mg/ml), pleura fluid (average 41.4 mg/ml; range
11.6–57.9 mg/ml) and plasma (average 71.6 mg/ml; range
11.9–106 mg/ml) samples obtained from the study subjects
was determined using the bicinchoninic acid (BCA) assay
(Pierce, Thermo Scientific, Rockford, USA) according to the
manufacturer's instructions. To adjust for dilution of the BAL
fluid, the total protein content in BAL samples was used to
normalize data obtained with the multiplex luminex assay
[18]. Normalized data of the BAL fluid samples are expressed
as pg/mg of total protein.
2.8. mRNA extraction and real-time PCR
Cell samples were stored in RNAlater until RNA was
extracted using the Ambion RiboPure extraction kit (Life
Technologies) according to the manufacturer's instructions.
RNA was reverse transcribed to cDNA using superscript
reverse transcriptase (Invitrogen). Amplification of target
genes using primers (Sigma Genosys, St. Louis, MO) for
β-actin (Forward: 5′-TTGCCGACAGGATGCAGAA-3′, Reverse:
5′-GCCGATCCACACGGAGTACT-3′), SOCS1 (Forward: 5′-TTTT
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AGTC-3′) and SOCS3 (Forward: 5′-TGAGCGCGGCTACAGC
TT-3′, Reverse: 5′-TCCTTAATGTCACGCACGATTT-3′) was
performed using SYBR Green JumpStart (Sigma, St. Louis,
MO) and the ABI PRISM 7700 Sequence Detection System
including the 7500 software v2.0.6 (Applied Biosystems,
Foster City, CA). The specificity of the PCR reactions was
verified by post-amplification melting-curve analysis. The Ct
(cycle threshold) values for SOCS1 and SOCS3 mRNA were
normalized to β-actin to provide the delta Ct values. The
relative mRNA expression was determined using the Livak
method (the 2−ΔΔCT method for real-time PCR). The data
are presented as fold change of mRNA in the pulmonary or
pleural TB groups compared to controls.
2.9. Human primary cells
PBMCs were isolated from ten healthy blood donors
(Karolinska University Hospital Blood Center, Stockholm,
Sweden) using density gradient centrifugation (Lymphoprep,
Axis-Shield, Norway). Monocyte Enrichment solution from
RosetteSep (Stemcell Technologies, Grenoble, France) was
used for purification of monocytes from six of the healthy
donors. Isolated monocytes were differentiated to macro-
phages in DMEM medium (Invitrogen) supplemented with
recombinant human M-CSF (50 ng/ml) (Stemcell Technolo-
gies, Reston, VA) for 6 days.
2.10. Bacterial cultures and infection of human cells
M. tuberculosis strain H37Rv (American Type Culture
Collection) was cultured in Middlebrook 7H9 broth supple-
mented with 10% OADC (BD), 0.05% Tween-80 (Sigma) and
0.5% glycerol (Sigma-Aldrich) for 2–3 weeks at 37 °C. The
bacterial suspension was washed twice in PBS-0.05%
Tween-80 before the pellet was resuspended in plain DMEM
medium. To obtain a single cell suspension, the bacteria
were repeatedly vortexed and sonicated using an ultrasound
sonication bath. The bacterial concentration was deter-
mined from the OD of the culture obtained at 600 nm, as a
function of colony forming units per milliliter. PBMCs were
cultured in 24-well plates (2 × 106 cells/well) in the
presence (MOI:5 and MOI:10) or absence of bacteria while
human primary macrophages were cultured in 24-well plates
(2 × 106 cells/well) and infected with the bacteria (MOI:5
and MOI:10) for 1–2 h before the cells were washed to
remove extracellular bacteria. Macrophage as well as PBMC
cultures were incubated in RPMI-10% FCS (GIBCO, Invitrogen)
at 37 °C for 4 h and 24 h before harvest of the cells for
mRNA analysis.
2.11. Statistical analysis
The multiplex luminex protein data are presented as log10
values in scatter dot plot graphs showing the median for
each individual while the mRNA data are presented as log10
values in box and whisker plots showing the median and
range. Non-parametric analyses were used to calculate
the indicated p-values for non-normally distributed data
(D'Agostino & Pearson omnibus normality test) and included
the Kruskal–Wallis test and Dunn's post-test or the MannWhitney test. Spearman's correlation test was used for the
correlation analysis. A value of r = 1, indicates a perfect
positive correlation whereas r = −1 indicates a perfect
negative correlation. Statistical analyses were performed
in GraphPad Prism-5.3. Results
3.1. Elevated pro-inflammatory and Th2 cytokine
responses in the absence of a Th1 response locally
in the lung of patients with active pulmonary TB
The clinical demographics of pulmonary and extrapulmonary
TB patients as well as controls are summarized in Table 1. TB
was confirmed using clinical and pathologic–anatomic diag-
noses and/orM. tuberculosis culture. Approximately one third
of the patients were TB/HIV co-infected and showed a low
peripheral CD4+ T cell count (Table 1). Multiplex protein
analysis revealed that the pro-inflammatory cytokines IL-1β,
IL-6 and TNF-α were significantly higher (p b 0.05–0.001) in
BAL fluid samples from patients with active pulmonary TB
compared to the controls (Fig. 2A), while only IL-6 was
significantly elevated (p b 0.01–0.001) in plasma samples
from the TB patients (Fig. 2A). Despite the elevation of these
pro-inflammatory markers in the lung of patients with active
TB, we could not detect elevated levels of IL-12 or IL-2 (data
not shown). Similarly, no increase in IFN-γ or IL-17 was
observed in the lungs of patients with active TB (Fig. 2B).
However, the multiplex analysis revealed higher plasma levels
of IFN-γ in TB/HIV co-infected patients compared to controls
but lower plasma levels of IL-17 in TB/HIV co-infected patients
as compared to TB infected patients (Fig. 2B). In contrast, IL-4
was significantly elevated in both BAL (p b 0.01) and plasma
(p b 0.05) samples from TB patients as compared to the
controls (Fig. 2B). Altogether, we found an 8–10 fold increase
in IL-1β and IL-6 and a 2–3 fold increase in TNF-α and IL-4 in
BAL fluid from patients with pulmonary TB, which denote
potent pro-inflammation and a predominant Th2 or a mixed
Th1/Th2 response in active TB.
3.2. Local chemokine responses in the lung of
patients with active pulmonary TB demonstrates
elevated levels of CXCL9, CXCL10 and CCL4 but lack
of CCL5
Consistent with the observed pro-inflammatory signature
(Fig. 2A), we also detected increased levels of the CXC
inflammatory chemokine CXCL8 (IL-8) in all TB patients (data
not shown). Despite the lack of IFN-γ up-regulation in the lung
of patients with active TB, the IFNγ-inducible inflammatory
chemokines, CXCL9 (MIG) and CXCL10 (IP-10), were increased
(p b 0.05–0.001) in both BAL (15–20 fold increase) and plasma
(6–8 fold increase) from pulmonary TB patients (Fig. 3).
However, the amounts of both CXCL9 and CXCL10 were
significantly higher (p b 0.05–0.01) in plasma samples from
TB/HIV co-infected patients (Fig. 3), which is in line with the
increased plasma levels of IFN-γ (3-fold increase) observed in
these patients (Fig. 2B). Among the CC chemokines, only CCL4
(MIP-1β) was significantly higher (p b 0.01) in BAL samples
from patients with active TB compared to controls (Fig. 3).
Table 1 Clinical demographics of included study subjects.
Clinical features Pulmonary TB patients and controls Pleural TB patients and controls
HIV-neg HIV-pos Controls HIV-neg HIV-pos Controls
Numbers 22 13 10 16 7 5
Age in years
(median with range)
24 (20–51) 38 (18–54) 26 (18–46) 25 (18–72) 35 (28–56) 40 (25–60)
Male/female gender 12/10 7/6 5/5 9/7 2/5 2/3
Clinical TB diagnosis
(no. (%)) a
22 (100%) 13 (100%) 0 (0%) 16 (100%) 7 (100%) 0 (0%)
Abnormal chest X-ray
(no. (%)) b
22 (100%) 13 (100%) 0 (0%) 16 (100%) 7 (100%) 5 (100%)
Positive Mtb culture of
BAL (no. (%)) c
16 (73%) 8 (62%) 0 (0%) nd nd nd
Positive Mtb cyto-histopathology
(no. (%)) d
nd nd nd 16 (100%) 7 (100%) 0 (0%)
CD4 T cell counts e
(mean with range)
685
(183–1333)
130
(10–279)
693
(593–806)
418
(166–906)
196
(49–457)
659
(298–1123)
CD8 T cell counts e
(mean with range)
576
(102–1902)
669
(57–1773)
599
(234–1288)
302
(84–845)
642
(124–2000)
940
(433–1712)
HIV viral load f
(median with range)
nd 40,000
(2.6 × 103–
1.2 × 106)
nd nd 18,000
(0.3 × 103–
0.4 × 106)
nd
Mtb, M. tuberculosis; nd, not determined.
a Diagnosis of clinical TB was based on clinical symptoms of more than 4 weeks duration (persistent cough, general illness, fever, sweating,
and weight loss) and response to standard anti-TB treatment (clinical recovery and resolution of lesions evident on the chest X-ray).
b Abnormal radiologic chest X-ray findings included pulmonary infiltrates/dense lesions or pleural effusions.
c Bronchoscopy was performed not only on pulmonary TB patients with an abnormal chest X-ray, but also on individuals with a normal
chest X-ray who had a minor hemoptysis caused by a minor bronchial wall irritation.
d Pleural controls with pleural diseases other than TB all had abnormal chest X-ray finings and included malignancies (n = 3), congestive
heart failure (n = 1) and systemic lupus erythematosus (n = 1).
e T cell counts in peripheral blood were determined as cells/mm3.
f HIV viral load in plasma from TB/HIV co-infected patients was determined as number of viral copies/ml.
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detected in all patients with active TB, the levels were not
significantly different compared to the control group (Fig. 3).
Hence, CCL4 was found to be the only chemokine selectively
up-regulated (5-fold increase) in the local environment of the
M. tuberculosis-infected lung.
3.3. Elevated levels of IL-4 and CCL4 are associated
with more severe forms of clinical TB disease
In order to analyze whether specific cytokine/chemokine
responses could be linked to severity of TB, pulmonary TB
patients were grouped into mild or moderate-to-severe
disease based on their chest X-ray results. A greater proportion
of patients with moderate-to-severe TB disease were culture
positive for M. tuberculosis (81%) compared to patients with
mild TB disease (58%). Interestingly, we observed that IL-1β
(data not shown), IL-4 and CCL4 were significantly increased
(p b 0.05–0.01) at the site of infection in HIV-negative
patients with moderate-to-severe compared to mild TB
disease (Fig. 4A). Although we detected significantly elevated
levels of both IL-4 and CCL4 in TB/HIV co-infected patients
(Fig. 2B, 3), there was no difference in IL-4 or CCL4 levels in
moderate-to-severe compared to mild TB disease in these
patients (Fig. 4A). This may be due to limitations in theradiological scoring system in TB/HIV co-infected patients.
Next, we assessed clinical samples from patients with extra-
pulmonary pleural TB (Table 1), which is generally considered
to be a less severe disease compared to pulmonary TB [17].
Interestingly, multiplex analysis of pleural fluid samples
revealed that both IL-4 and CCL4 remained unaltered in
patients with extrapulmonary pleural TB as compared to the
controls, while IFN-γ and CCL5 were significantly increased
(p b 0.05–0.001) in both HIV-negative (15-fold and 3-fold
increase, respectively) and HIV-positive (10-fold and 2-fold
increase, respectively) patients with a local TB pleuritis
(Fig. 4B). These findings suggest that the immune response is
shifted towards a Th2 profile in TB, particularly in patients
with more advanced clinical TB disease.
3.4. A predominant Th2 response in patients with
active pulmonary TB correlates to aM. tuberculosis-
specific antibody response
To study whether a shift towards a Th2 profile in patients
with active pulmonary TB concurred with a humoral immune
response, we assessed the presence of mycobacteria-
specific IgG antibodies in TB patients and controls. Inter-
estingly, significantly elevated levels of BCG-specific IgG
antibodies were detected in BAL (p b 0.05–0.01) and
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Figure 2 Elevated pro-inflammatory and Th2 cytokine responses in patients with active pulmonary TB (PTB). Assessment of (A)
pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and (B) effector cytokines (IFN-γ, IL-17 and IL-4) in BAL fluid and plasma samples
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dot-plots and the solid bars indicate the median values for each group. The statistical significance of differences in cytokine
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One out of three similar experiments is shown.
90 S. Ashenafi et al.plasma (p b 0.01–0.001) samples from both HIV-negative
and HIV-positive TB patients (Fig. 5A). Accordingly, there
was a significant correlation between BCG-specific IgG
levels and IL-4 in BAL fluid (r = 0.55; p = 0.008) and plasma
(r = 0.42; p = 0.05) samples from HIV-negative patients
with active pulmonary TB (Fig. 5A). There was also a
significant correlation between BCG-specific IgG levels and
CCL4 in BAL fluid (r = 0.47; p = 0.03), but not in plasma
from HIV-negative TB patients (Fig. 5B), which may
illustrate preferential recruitment of IgG secreting cells to
the site of M. tuberculosis infection in the lung. We also
found that BCG-specific IgG levels determined in plasma
were significantly higher (p = 0.0003) in patients with
pulmonary TB compared to patients with extrapulmonary
pleural TB (Fig. 5C), which is consistent with higher levels of
IL-4 and CCL4 in pulmonary TB. Pleural TB patients did not
present elevated BCG-specific IgG titres compared to the
controls (data not shown). These data support a biastowards a Th2-driven antibody response, particularly in
HIV-negative patients with pulmonary TB.3.5. A Th2 response in patientswith active pulmonary
TB is associated with an elevated expression of SOCS3
To explore whether expression of SOCS was associated with
immune polarization towards an IL-4/CCL4 response signature
in patients with active TB, we analyzed the mRNA accumula-
tion of SOCS1 and SOCS3 in BAL and pleural cells as well as
PBMCs samples from patients with active TB and control
individuals. Strikingly, both SOCS1 and SOCS3 mRNA levels
were significantly up-regulated (p b 0.05–0.01) in BAL cells
from pulmonary TB patients (Fig. 6A); while no increase in
SOCS was evident in the PBMCs (data not shown). However,
SOCS1 expression was not associated with severity of
pulmonary TB disease, whereas SOCS3 expression was
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Figure 3 Induced chemokine expression of CXCL9, CXCL10 and CCL4 but not CCL5 in patients with active pulmonary TB (PTB).
Assessment of chemokine (CXCL9, CXCL10, CCL4 and CCL5) responses in BAL fluid and plasma samples from HIV-negative and
HIV-positive patients with active PTB (circles) and controls (triangles). Graphs are presented as scatter dot-plots and the solid bars
indicate the median values for each group. The statistical significance of differences in chemokine expression in vivo between the
different groups was determined using the Kruskal–Wallis test, *p b 0.05, **p b 0.01 and ***p b 0.001. One out of three similar
experiments is shown.
91A Th2 immune signature and elevated SOCS3 in active TBsignificantly enhanced (p b 0.05–0.01) in HIV-negative pa-
tients with moderate-to-severe compared to mild TB disease
(Fig. 6B). Importantly, there was a significant correlation
between SOCS3 mRNA expression in BAL cells and IL-4 as well
as CCL4 in BAL fluid samples (r = 0.37; p = 0.03 and r = 0.48;
p = 0.004, respectively) (Fig. 6), but not between SOCS1 and
IL-4 or CCL4 (data not shown). In line with these findings,
pleural fluid cells from patients with extrapulmonary pleural
TB had increased SOCS1 but not SOCS3 mRNA levels (Fig. 6D),
which also supports the conclusion that SOCS3 is a marker of
more severe or advanced forms of clinical TB disease. In
summary, SOCS1 was up-regulated in both pulmonary TB
(Fig. 6A) and pleural TB (Fig. 6D), while SOCS3 was only
up-regulated in pulmonary TB (Fig. 6A and D) and also in
moderate-to-severe forms of pulmonary TB disease (Fig. 6B).
These results confirm an association between IL-4, CCL4 and
SOCS3 in patients with active pulmonary TB.
3.6. M. tuberculosis induces both SOCS1 and SOCS3
expression in human PBMCs and macrophages
Since increased levels of SOCS mRNA were only evident in
cells from the site of M. tuberculosis infection, we isolated
PBMCs or monocytes from healthy individuals to investigate
SOCS mRNA expression in response to mycobacteria in vitro.
Exposure of PBMCs or infection of blood-derived macro-
phages with virulent H37Rv revealed that SOCS1 and SOCS3
were significantly induced (p b 0.01–0.001) in both PBMC
(Fig. 7A) and macrophage (Fig. 7B) cultures. The induction of
both SOCS molecules were 100–1000 fold higher in macro-
phages compared to PBMCs (Fig. 7), which imply that SOCS
are rapidly and strongly up-regulated primarily in macro-
phages productively infected with M. tuberculosis.
4. Discussion
To get a proper reflection of M. tuberculosis-specific immune
responses induced at local sites, human TB disease needs to beexplored using relevant clinical materials obtained from the
site of infection or from areas close to the infected sites
[3,8,17,19,20]. In this study, we show for the first time that
the local immune response in the lung of patients with
pulmonary TB is associated with impaired Th1/Th17 cytokine
responses but elevated levels of IL-4, CCL4 and the regulatory
proteins SOCS1 and SOCS3. This Th2-like immune response
signature correlates to enhanced mycobacteria-specific IgG
responses. Furthermore, IL-4, CCL4 and SOCS3 were elevated
in HIV-negative patients with moderate-to-severe pulmonary
TB as compared tomild disease, which support the notion of an
aberrant immune response in the progression of clinical TB.
Importantly, we observed an induction of a Th1 response in the
absence of Th2 response in less severe forms of extra-
pulmonary pleural TB disease. Accordingly, pleural TB patients
also lacked up-regulation of SOCS3 and mycobacteria-specific
IgG. In summary, our results suggest that the local immune
response in theM. tuberculosis infected lung is dominated by a
Th2 type inflammation in combination with SOCS3 that may
contribute to the failure of immune control in patients with
progressive clinical TB.
Despite strong pro-inflammation including high local
levels of IL-1β, IL-6 and TNF-α, there was a decreased
Th1/Th2 cytokine ratio in patients with active TB. We
demonstrate that IL-6 and IL-4 were up-regulated both in
peripheral blood and locally in the M. tuberculosis-infected
lung, where we also found a significant correlation (r = 0.40;
p b 0.01) between these cytokines. Similar to IL-12, IL-6 is
abundantly produced by APCs and may therefore participate
in the early events of Th1/Th2 development. However, in
contrast to IL-12, IL-6 has been described to polarize naive
CD4+ T cells into IL-4 producing Th2 effector cells [21,22]
and IL-6 could also inhibit Th1 differentiation and interfere
with IFN-γ signaling by specific induction of SOCS1 in
activated CD4+ T cells [22]. Similarly, IL-1β can also act
directly on CD4+ T cells to promote the differentiation of
IL-4-producing Th2 cells upon infection with virulent
M. tuberculosis [23]. Interestingly, while TNF-α clearly has
a protective role in TB, the presence of IL-4 may enhance
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Figure 4 Increased expression of IL-4 and CCL4 in patients with moderate-to-severe pulmonary TB (PTB) disease but not in patients
with extrapulmonary TB (EPTB). (A) Comparison of IL-4 and CCL4 expression in BAL fluid samples from HIV-negative and HIV-positive
patients with mild PTB (open circles) to patients with moderate-to-severe PTB (gray circles). Disease severity in HIV-negative PTB
with mild (n = 12) or mod–sev (n = 10) disease and in HIV-positive PTB patients with mild (n = 7) or mod–sev (n = 6) disease was
determined using chest X-ray. (B) Assessment of cytokine (IL-4 and IFN-γ) and chemokine (CCL4 and CCL5) responses in pleural fluid
samples from HIV-negative and HIV-positive EPTB patients with a local TB pleuritis (circles) and controls (triangles). Graphs are
presented as scatter dot-plots and the solid bars indicate the median values for each group. The statistical significance of differences
in cytokine/chemokine expression in vivo between the different groups was determined using the Kruskal–Wallis test. *p b 0.05,
**p b 0.01 and ***p b 0.001. One out of three similar experiments is shown.
92 S. Ashenafi et al.TNF-α mediated immunopathology in progressive disease
[24,25].
Previous studies that have investigated the Th1/Th2
balance in patients with active TB do not provide a consistent
view on cytokine polarization in human TB [26–32]. The
observed discrepancies may be due to differences in patients'
ethnicity and clinical form of TB disease, analysis of cells or
serum samples, ex vivo analysis or recall T cell responses in
vitro, the method of analysis used etc. Consistent with our
results, increased levels of IL-4 have previously been found in
the blood [30,33,34] and BAL [31,35] of TB patients withadvanced compared tomild-to-moderate lung disease and IL-4
levels were also associated with elevated antibody responses
in the serum [34]. Progression of clinical TB disease could also
involve a mixed Th1/Th2 response that may impair bacteri-
cidal function and promote pulmonary fibrosis [7,8,17,25,36].
It was recently described that patients with multi-drug
resistant TB (MDR-TB) had down-regulated expression of
IFN-γ and IL-2 in the lung, but instead up-regulated IL-4,
IL-6, and TNF-α expression during progressive disease [37].
Accordingly, certain MDR outbreak strains induce a weak IFN-γ
but strong IL-4 response, which correlates to reduced CTL
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Figure 5 Enhanced BCG-specific IgG antibody response in patients with active pulmonary TB (PTB). (A) Assessment of BCG-specific
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93A Th2 immune signature and elevated SOCS3 in active TBactivity of these MDR-TB patients [38]. Consequently, the
virulence of different M. tuberculosis strains may affect
cytokine polarization and disease outcome [39]. A patholog-
ical role of IL-4 is also evident in TB-susceptible contacts,
where a rise in serum IL-4 concurrent with low IFN-γ is
associated with development of active TB disease [40].
Likewise, pleural TB is characterized by local production of
IFN-γ and a predominant Th1 response, while miliary or
systemic TB is characterized by local IL-4 production in the
lung and a shift towards a Th2 response [8]. Whether
Th2-driven inflammation is a cause or effect of TB disease is
not known. Individuals with a higher basal production of Th2
cytokines may be predisposed to develop active TB disease,
which has been observed in patients with helminth infections
[41]. Accordingly, Th2 responses that are experimentally
introduced in mice before infection with M. tuberculosis will
result in enhanced disease severity and death, which supports
the notion that the Th2 response is a cause rather than an
effect of TB [42,43]. However, enhanced Th2 polarizationmay
also be the consequence of progressive TB disease, when
impairment of Th1 responses results in a failure to antagonize
Th2-induced immunity.
The increased antibody response we observed in TB/HIV
co-infected patients did not seem to correlate with IL-4
production, which may suggest that humoral immunity inthis group of patients, is regulated by factors other than
IL-4. High serum levels of total [44] and M. tuberculosis-
specific [45] IgG antibodies have previously been shown in
patients with TB/HIV co-infection. Interestingly, a splice
variant and competitive antagonist of IL-4, IL-4delta2, has
been described to be expressed at elevated levels in BAL
fluid but not in peripheral blood from TB/HIV co-infected
patients [46]. These results imply that there may be a
selective increase of IL-4 in the periphery of TB/HIV co-
infected patients [46]. Although our multiplex analysis could
not separate IL-4 from IL-4delta2 expression, it is tempting
to speculate that a higher IL-4/IL-4delta2 ratio in the lung of
TB single-infected compared to TB/HIV co-infected patients
could undermine the efficacy of a local Th1 response and
promote antibody responses, particularly in the lung of HIV-
negative patients with pulmonary TB. The IL-4/IL-4delta2
ratio has been shown to be decreased in individuals with
latent TB [47], thus this cytokine ratio may be useful as a
marker for disease activity.
Analysis of the chemokine response in our study cohort
revealed that the inflammatory chemokines CXCL8, CXCL9
and CXCL10 (IP-10) were significantly higher in patients with
active pulmonary TB. Importantly, even very low levels of
IFN-γ can promote high levels of CXCL10 [48], which could
explain high levels of CXCL9 and CXCL10 in the absence of
94 S. Ashenafi et al.IFN-γ up-regulation. Alternatively, an early transient rise of
IFN-γ in the lung of M. tuberculosis-infected patients may be
sufficient to induce CXCR3 ligands, but insufficient to establish
protective Th1 immunity. Furthermore, it has been shown that
CXCR3 ligands can be induced by other cytokines than IFN-γ,
including IL-27, TNF-α [49], IL-12 [48] and IFNα/β [50]. Here,
increased levels of IL-27 correlated with enhanced CXCL10A SOCS1
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)production in BAL from pulmonary TB patients [49]. Interest-
ingly, regulatory DCs that produce CXCL10 have been shown to
attract Th1 cells and inhibit Th1 responses [50]. Furthermore,
CXCL9 knock-out mice do not have impaired control of
intracellular infections, but rather CXCL9 was important for
antibody responses to extracellular bacteria [51]. In contrast,
CCL5 has been shown to significantly enhance CTL activity [52]SOCS3
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Figure 7 Induction of SOCS1 and SOCS3 mRNA expression in PBMCs exposed to M. tuberculosis as well as in M. tuberculosis-infected
human primary macrophages. (A) PBMCs were isolated from the blood of healthy donors (n = 10) and exposed to M. tuberculosis
H37Rv for 4 h or 24 h before assessment of SOCS mRNA. (B) In parallel, primary macrophages were differentiated from the same
donors (n = 6) and infected with H37Rv for 1–2 h before extracellular bacteria were washed away and SOCS mRNA was assessed after
4 h and 24 h. mRNA data are presented in box and whisker plots showing the median and range from n = 6–10 donors in each group.
The statistical significance of differences in SOCS mRNA expression in vitro between the different groups was determined using the
Kruskal–Wallis test, ns p N 0.05, **p b 0.01 and ***p b 0.001.
95A Th2 immune signature and elevated SOCS3 in active TBand migration of effector CD8+ T cells [53] as well as
M. tuberculosis-infected macrophages [54] to the lung. Thus,
the lack of CCL5 as well as CCL2 and CCL3, which are key
chemoattractants of monocytes, neutrophils and T cells, may
partly explain the impaired Th1 immune response observed in
patients with active pulmonary TB [55]. Recent data also
suggest that IL-17-dependent induction of CXCL13 in the
M. tuberculosis-infected lung may enhance Th1 effector
functions andmacrophage activation in TB inflammatory lesions
[56]. CXCL13 promotes local recruitment of CXCR5+ T cells thatFigure 6 Elevated mRNA expression of SOCS1 and SOCS3 in patient
levels in BAL cell samples from HIV-negative and HIV-positive patie
SOCS3 mRNA expression in BAL cell samples from HIV-negative and H
moderate-to-severe PTB (gray bars). Disease severity in HIV-negat
HIV-positive PTB patients with mild (n = 7) or mod–sev (n = 6) dise
between SOCS3 mRNA and IL-4 or CCL4 protein levels in BAL cell and
Spearman's correlation test was used to determine the correlation co
and SOCS3 mRNA levels in cell samples from pleural fluid obtained f
pleuritis and controls. mRNA data are presented in box and whisker p
significance of differences in SOCS mRNA expression in vivo betwee
test, ns p N 0.05, *p b 0.05, **p b 0.01 and ***p b 0.001. One out of texpress high levels of Th1 cytokines including IFN-γ, TNF-α and
IL-2 in the M. tuberculosis-infected lung [57], which underline
the importance of continued studies of both chemokines and
their receptor expression in the local tissue environment.
Although we did not find a major impact of HIV infection on
the local immune response in the lung of patients with active
TB, plasma levels of CXCL9 and CXCL10 were particularly high
in TB/HIV co-infected patients. Accordingly, we found a
negative correlation between CXCL9 and CXCL10 levels
and peripheral CD4 T cell counts (r = −0.69; p b 0.0001 ands with active pulmonary TB (PTB). (A) Assessment of SOCS mRNA
nts with active PTB and controls. (B) Comparison of SOCS1 and
IV-positive patients with mild PTB (open bars) to patients with
ive PTB with mild (n = 12) or mod–sev (n = 10) disease and in
ase was determined using chest X-ray. (C) Correlation analysis
fluid samples from HIV-negative and HIV-positive PTB patients.
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96 S. Ashenafi et al.r = −0.75; p b 0.0001). Previously it has been shown that the
number of CD4+ T cells is also significantly reduced in BAL
fluid from HIV-positive compared to HIV-negative patients
with pulmonary TB [58], which may result in reduced local
levels of IFN-γ and prevent the induction of an effective
immune response. However, high CXCL10 levels in TB/HIV
co-infected subjects are less dependent on CD4 T cell counts
than IFN-γ levels [59,60], perhaps due to CXCL10 production
by monocytes and macrophages rather than T cells.
In the panel of chemokines tested, we found a predominant
local expression of CCL4 in the BAL fluids obtained from M.
tuberculosis-infected lungs. Interestingly, the CCL4 gene
demonstrates significant association with increased suscepti-
bility to TB [61] and accumulating data provide evidence of an
immunoregulatory role of CCL4 [14,62]. IL-4 specifically
elevates CCL4 expression and supports polarization of regula-
tory Th2 cells in vivo, which protects diabetic mice from
developing inflammation and destructive disease [63–65].
Accordingly, diabetic TB patients who experienced a fast
deterioration in their clinical TB disease showed a bias towards
a Th2 response [66]. Remarkably, islet-specific Th1 cells were
able to produce CCL2, CCL3, CCL4 and CCL5, while Th2 cells
only produced CCL4 [67]. IL-4-induced CCL4 suppresses
Th1-mediated pathogenesis by decreasing the recruitment of
activated CD8+ T cells into pancreatic islets lesions, while
enhancing the recruitment of antigen-specific CD4+ Treg cells
[14,68]. Similarly, in vivo expression of CCL4 induced T cells to
produce less IFN-γ and more IL-4 [14], which resulted in
decreased local CTL responses but increased peripheral IgG
and IgA antibody responses after mucosal immunization
[69,70]. Other studies have shown that CCL4 is the most
potent chemoattractant of CD4+CD25+ Treg cells [71], while
human Treg cells secreting CCL4 can inhibit microbe-specific T
cell activation [62]. Interestingly, such CD8+LAG3+CCL4+ Treg
cells were shown to be enriched 20-fold in granulomas of M.
tuberculosis-infected lymph nodes [62].
Our findings show that both SOCS1 and SOCS3 inhibitory
proteins were up-regulated in pulmonary TB, while SOCS3
was more associated with severe forms of TB. Both SOCS1
and SOCS3 can be rapidly induced by i.e. TLR4-ligands and
mycobacteria can also trigger rapid production of pro-
inflammatory cytokines i.e. IL-1β and IL-6 that up-regulate
SOCS-expression [72]. It has previously been determined
that SOCS1 expression is 5-fold higher in Th1 than in Th2
cells, whereas Th2 cells contain 23-fold higher levels of
SOCS3 [73]. SOCS1 and SOCS3 can be induced in murine
macrophages upon infection with avirulent mycobacteria
[74,75], and our data suggest that SOCS1 and SOCS3 were
up-regulated in PBMCs as well as in macrophages upon
in vitro exposure or infection with virulent M. tuberculosis.
mRNA expression profiles in sputum samples from TB
patients demonstrated significantly higher levels of anti-
inflammatory mediators including both SOCS1 and SOCS3
[76]. In addition, gene expression profiles of human blood
samples revealed an accumulation of SOCS3 in active
TB compared to latent TB [77,78]. SOCS3 was reduced
simultaneously as IFN-γ was increased upon successful
chemotherapy in patients with active TB [76,77]. Interest-
ingly, previous research in both mice and humans has found a
mechanistic link between increased levels of SOCS3 and the
development and maintenance of Th2 cells. T cells from
patients with Th2-mediated allergy have a high SOCS3expression that correlates with disease pathology, including
the induction of humoral immunity [79]. Accordingly, Th2
responses were strongly elevated in SOCS3 transgenic mice
[79], while mice with SOCS3-deficient T cells produced less
IL-4 as well as antigen-specific IgG1 and IgE responses [80].
Deficient SOCS3-binding also results in an increased CCL5
expression and T cell recruitment to the site of inflammation
[81]. Consistently, SOCS3-deficient macrophages have a
stronger capacity to induce Th1 and Th17 cell differentiation
[82], while induction of SOCS3 in CD4+ T cells force a Th2
profile by preventing IL-12-induced Th1 differentiation [83].
SOCS3 inhibits IL-12-mediated STAT4 activation by binding to
the IL-12Rβ2 subunit and thus promotes Th2 polarization [84].
Contrary to these reports, recently published data suggest
that SOCS3-deficient mouse macrophages are converted to
alternatively activated M2-type [85], and that SOCS3 is critical
for resistance to M. tuberculosis infection in mice [86].
Apparently, further consensus regarding the role of SOCS
proteins in the establishment of TB as well as progression of
active disease is required, particularly in humans.
5. Conclusions
Altogether, the findings from this study demonstrate that a
low Th1-mediated immune response may be the result of an
inappropriate Th2-like immune response signature involving
enhanced expression of IL-4 and CCL4 in combination with
SOCS3. Excess expression of regulatory SOCS proteins in
human TB may contribute to Th2 immune polarization and
loss of important Th1 effector functions that could promote
intracellular persistence of M. tuberculosis. Th2 and SOCS3-
regulated immune response pathwaysmay be further explored
as potential targets for future clinical interventions.
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